share_log

BTIG Initiates Coverage On NexImmune with Buy Rating, Announces Price Target of $5

BTIG Initiates Coverage On NexImmune with Buy Rating, Announces Price Target of $5

BTIG以買入評級啓動對NexImmune的報道,宣佈目標股價爲5美元
Benzinga Real-time News ·  2022/06/01 07:30

BTIG analyst Kaveri Pohlman initiates coverage on NexImmune (NASDAQ:NEXI) with a Buy rating and announces Price Target of $5.

BTIG分析師卡維裏·波爾曼以買入評級開始對NexImmune(納斯達克股票代碼:NEXI)進行報道,並宣佈目標股價爲5美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論